Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians

Despite a decline in many forms of cardiovascular disease, heart failure (HF) continues to increase. Heart failure with preserved ejection fraction (HFpEF) is common, especially among persons with multiple comorbidities. HFpEF presents many challenges for clinicians due to the incomplete understandi...

Full description

Saved in:
Bibliographic Details
Published in:Hospital pharmacy (Philadelphia) 2015-06, Vol.50 (6), p.454-459
Main Author: Howard, Patricia A.
Format: Article
Language:English
Subjects:
Cardiovascular Therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite a decline in many forms of cardiovascular disease, heart failure (HF) continues to increase. Heart failure with preserved ejection fraction (HFpEF) is common, especially among persons with multiple comorbidities. HFpEF presents many challenges for clinicians due to the incomplete understanding of the underlying mechanisms and lack of consensus on the most effective strategies for treatment. Angiotensin and beta receptor-blocking drugs, which form the cornerstone for the treatment of systolic HF, have failed to show similar benefits in patients with impaired diastolic function. This article provides an overview of drug therapy for HFpEF, including newer agents now under investigation.
ISSN:0018-5787
1945-1253
DOI:10.1310/hpj5006-454